Bevacizumab for choroidal neovascularization related to inflammatory diseases

Retina

Volumn 30, Issue 6, 2010, Pages 938-944

  Kramer, Michal ^a,b   Axer Siegel, Ruth ^a,b   Jaouni, Tareq ^c   Reich, Ehud ^a,b   Hemo, Itzhak ^c,d   Priel, Ethan ^e   Averbukh, Edward ^c,d   Ehrlich, Rita ^a   Chowers, Itay ^c,d   Weinberger, Dov ^a,b   Amer, Radgonde ^c,d  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY   (Israel)

^e Mor Institute for Medical Data   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BEVACIZUMAB; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHORIORETINITIS; CHOROIDITIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; IRIDOCYCLITIS; MALE; OCULAR HISTOPLASMOSIS; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RETROSPECTIVE STUDY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 77953336820     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181c96a00     Document Type: Article

References (32)

1. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109: 1109-1114.
2. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994;112:500-509.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001; 119:198-207.
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report 3. Ophthalmology 2003;110:667-673.
5. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304. (Pubitemid 40202568)
6. Macular Photocoagulation Study Group. Argon laser photocoagulation for ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol 1983;101:1347-1357.
7. Postelmans L, Pasteels B, Coquelet P, et al. Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like). Ocul Immunol Inflamm 2005;13:361-366.
8. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteroids for choroidal neovascularisation in young patients. Eye (Lond) 1998;12(Pt 2):266-272.
9. Dees C, Arnold JJ, Forrester JV, Dick AD. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol 1998;116: 1456-1461.
10. Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina 2008;28:71-80.
11. Essex RW, Tufail A, Bunce C, Aylward GW. Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br J Ophthalmol 2007;91:649-654.
12. Watzke RC, Parker AJ, Folk JC, et al. Punctate inner chorioretinopathy. Am J Ophthalmol 1984;98:572-584.
13. Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2008;22: 761-767.
14. Valmaggia C, Niederberger H, Lang C, Kloos P, Haueter I. The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin). Klin Monatsbl Augenheilkd 2008;225:380-384.
15. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008;92: 1035-1039.
16. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-945.
17. Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B, Lehoang P. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 2008;246:1685-1692.
18. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008;146:410-416.
19. Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:l 180-1186. (Pubitemid 350211522)
20. Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 2009;29:8-12.
21. Kurup S, Lew J, Byrnes G, Yeh S, Nussenblatt R, Levy-Clarke G. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol 2009;87:349-352.
22. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
23. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19: 361-372.
24. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
25. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637.
26. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007; 143:977-983.
27. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-451.
28. Dunlop AAS, Cree IA, Hague S, Luthert PJ, Lightman S. Multifocal choroiditis: clinicopathologic correlation. Arch Ophthalmol 1998;116:801-803.
29. Kramer M. Photodynamic therapy for inflammatory CNV: do we know enough? Ocul Immunol Infiamm 2005;13: 331-333.
30. Figueroa MS, Noval S, Contreras I. Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab. Br J Ophthalmol 2008;92:1244-1247.
31. Hoeh AE, Schaal KB, Ach T, Dithmar S. Treatment of peripapillary choroidal neovascularization with intravitreal bevacizumab. Eur J Ophthalmol 2009;19:163-165.
32. Wickremasinghe SS, Michalova K, Gilhotra J, et al.Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915.